Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Portfolio Pulse from Benzinga Newsdesk
Eterna Therapeutics Inc. has entered into a securities purchase agreement with accredited investors to sell around $9.2 million in senior convertible promissory notes and warrants. These warrants allow for the purchase of approximately 9.58 million shares of common stock. The private placement transaction was priced at-the-market under Nasdaq rules. The company anticipates an initial closing with proceeds of about $7.8 million on December 15, 2023, and the remaining funds by January 15, 2023.

December 15, 2023 | 7:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eterna Therapeutics Inc. has announced a significant financing round through convertible debt and warrants, which is expected to bring in $9.2 million to fund its operations and research.
The announcement of the convertible debt and warrant financing is likely to be viewed positively by investors as it provides Eterna Therapeutics with additional capital to advance its research and development efforts. This influx of capital can be seen as a vote of confidence from investors and may lead to a short-term positive impact on ERNA's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100